FDA’s Pazdur is said to raise questions about commissioners actions, new vouchernews2025-11-24T21:04:48+00:00November 24th, 2025|Endpoints News|
Top Makary aide Jain-Nagpal remains at the FDA after White House pushbacknews2025-11-21T20:25:04+00:00November 21st, 2025|Endpoints News|
FDA investigates child death potentially related to Takeda’s enzyme replacement therapynews2025-11-21T16:11:24+00:00November 21st, 2025|Endpoints News|
FDA will allow email ‘clarifications’ after pharma company meetingsnews2025-11-20T14:34:56+00:00November 20th, 2025|Endpoints News|
FDA approves Bayer’s HER2-mutated lung cancer drugnews2025-11-19T20:28:57+00:00November 19th, 2025|Endpoints News|
Makary calls for ‘America First’ drug user fee renegotiationsnews2025-11-18T19:14:27+00:00November 18th, 2025|Endpoints News|
Arrowhead gets FDA approval for rare lipid disease drugnews2025-11-18T18:52:23+00:00November 18th, 2025|Endpoints News|
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing studynews2025-11-14T20:48:04+00:00November 14th, 2025|Endpoints News|
Onshoring and data ‘fidelity’: What FDA wants from generic drug user fee talksnews2025-11-14T20:47:05+00:00November 14th, 2025|Endpoints News|
CHMP endorses Sanofi diabetes drug, Lilly breast cancer treatmentnews2025-11-14T19:42:51+00:00November 14th, 2025|Endpoints News|
